NeuroAllergy Research Laboratory (NARL), School of Life and Environmental Sciences, Faculty of Science, Engineering and Built Environment, Deakin University, 75 Pigdons Road, Geelong 3216 VIC, Australia.
Int J Mol Sci. 2020 Jul 16;21(14):5010. doi: 10.3390/ijms21145010.
Hypersensitivity or an allergy to chicken egg proteins is a predominant symptomatic condition affecting 1 in 20 children in Australia; however, an effective form of therapy has not yet been found. This occurs as the immune system of the allergic individual overreacts when in contact with egg allergens (egg proteins), triggering a complex immune response. The subsequent instantaneous inflammatory immune response is characterized by the excessive production of immunoglobulin E (IgE) antibody against the allergen, T-cell mediators and inflammation. Current allergen-specific approaches to egg allergy diagnosis and treatment lack consistency and therefore pose safety concerns among anaphylactic patients. Immunotherapy has thus far been found to be the most efficient way to treat and relieve symptoms, this includes oral immunotherapy (OIT) and sublingual immunotherapy (SLIT). A major limitation in immunotherapy, however, is the difficulty in preparing effective and safe extracts from natural allergen sources. Advances in molecular techniques allow for the production of safe and standardized recombinant and hypoallergenic egg variants by targeting the IgE-binding epitopes responsible for clinical allergic symptoms. Site-directed mutagenesis can be performed to create such safe hypoallergens for their potential use in future methods of immunotherapy, providing a feasible standardized therapeutic approach to target egg allergies safely.
对鸡蛋白过敏是一种常见的症状,在澳大利亚,每 20 个孩子中就有 1 个会受到这种症状的影响;然而,目前还没有找到有效的治疗方法。这种情况是由于过敏个体的免疫系统在接触到过敏原(鸡蛋蛋白)时过度反应,引发复杂的免疫反应。随后的即时炎症免疫反应的特征是针对过敏原的免疫球蛋白 E(IgE)抗体、T 细胞介质和炎症的过度产生。目前针对鸡蛋过敏的过敏原特异性诊断和治疗方法缺乏一致性,因此给过敏患者带来了安全隐患。免疫疗法是迄今为止治疗和缓解症状最有效的方法,包括口服免疫疗法(OIT)和舌下免疫疗法(SLIT)。然而,免疫疗法的一个主要局限性是从天然过敏原来源制备有效和安全提取物的困难。分子技术的进步使得通过针对引起临床过敏症状的 IgE 结合表位,生产安全和标准化的重组和低变应原性鸡蛋变体成为可能。可以进行定点突变,以创建这些安全的低变应原,为未来的免疫治疗方法提供潜在的应用,为安全靶向鸡蛋过敏提供可行的标准化治疗方法。